JP7181193B6 - 抗ｃｈｉｋｖ抗体およびその使用 - Google Patents

抗ｃｈｉｋｖ抗体およびその使用 Download PDF

Info

Publication number
JP7181193B6
JP7181193B6 JP2019521142A JP2019521142A JP7181193B6 JP 7181193 B6 JP7181193 B6 JP 7181193B6 JP 2019521142 A JP2019521142 A JP 2019521142A JP 2019521142 A JP2019521142 A JP 2019521142A JP 7181193 B6 JP7181193 B6 JP 7181193B6
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
amino acid
chikv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521142A
Other languages
English (en)
Japanese (ja)
Other versions
JP7181193B2 (ja
JP2019534001A (ja
JP2019534001A5 (enExample
Inventor
カラ・カーター
センドリーヌ・ルモワンヌ
マリー・マンドロン
サングヘー・パーク
ファーウェイ・チウ
ジョナサン・ロスブラット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2019534001A publication Critical patent/JP2019534001A/ja
Publication of JP2019534001A5 publication Critical patent/JP2019534001A5/ja
Priority to JP2022183022A priority Critical patent/JP7664212B2/ja
Application granted granted Critical
Publication of JP7181193B2 publication Critical patent/JP7181193B2/ja
Publication of JP7181193B6 publication Critical patent/JP7181193B6/ja
Priority to JP2024218402A priority patent/JP2025038079A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019521142A 2016-10-20 2017-10-19 抗ｃｈｉｋｖ抗体およびその使用 Active JP7181193B6 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022183022A JP7664212B2 (ja) 2016-10-20 2022-11-16 抗ｃｈｉｋｖ抗体およびその使用
JP2024218402A JP2025038079A (ja) 2016-10-20 2024-12-13 抗ｃｈｉｋｖ抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306374.6 2016-10-20
EP16306374 2016-10-20
PCT/EP2017/076792 WO2018073387A1 (en) 2016-10-20 2017-10-19 Anti-chikv antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183022A Division JP7664212B2 (ja) 2016-10-20 2022-11-16 抗ｃｈｉｋｖ抗体およびその使用

Publications (4)

Publication Number Publication Date
JP2019534001A JP2019534001A (ja) 2019-11-28
JP2019534001A5 JP2019534001A5 (enExample) 2020-11-26
JP7181193B2 JP7181193B2 (ja) 2022-11-30
JP7181193B6 true JP7181193B6 (ja) 2022-12-13

Family

ID=57590434

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019521142A Active JP7181193B6 (ja) 2016-10-20 2017-10-19 抗ｃｈｉｋｖ抗体およびその使用
JP2022183022A Active JP7664212B2 (ja) 2016-10-20 2022-11-16 抗ｃｈｉｋｖ抗体およびその使用
JP2024218402A Pending JP2025038079A (ja) 2016-10-20 2024-12-13 抗ｃｈｉｋｖ抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022183022A Active JP7664212B2 (ja) 2016-10-20 2022-11-16 抗ｃｈｉｋｖ抗体およびその使用
JP2024218402A Pending JP2025038079A (ja) 2016-10-20 2024-12-13 抗ｃｈｉｋｖ抗体およびその使用

Country Status (12)

Country Link
US (2) US11286295B2 (enExample)
EP (1) EP3529271A1 (enExample)
JP (3) JP7181193B6 (enExample)
CN (2) CN115873106A (enExample)
AR (1) AR109857A1 (enExample)
CA (1) CA3040842A1 (enExample)
EA (1) EA201990988A1 (enExample)
IL (2) IL266082B2 (enExample)
MA (1) MA46562A (enExample)
TW (2) TW202300515A (enExample)
UY (1) UY37449A (enExample)
WO (1) WO2018073387A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41517A (fr) * 2015-04-14 2017-12-19 Univ Vanderbilt Neutralisation du virus du chikungunya à médiation par des anticorps
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
WO2019156758A2 (en) 2018-01-05 2019-08-15 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
KR102201261B1 (ko) * 2019-05-15 2021-01-11 한국생명공학연구원 치쿤구니야 바이러스에 특이적인 단일클론 항체 및 이의 용도
CN114656554B (zh) * 2022-03-07 2023-05-23 中山大学 基孔肯雅热病毒e2蛋白的纳米抗体及其应用
CN118956771A (zh) * 2024-04-24 2024-11-15 华南农业大学 一种杂交瘤细胞株、基孔肯雅病毒单克隆抗体及其制备方法与应用
KR102830571B1 (ko) * 2024-12-20 2025-07-09 대한민국(질병관리청 국립보건연구원장) 치쿤구니아 바이러스 외피 재조합 단백질을 포함하는 치쿤구니아열 백신 조성물
CN119841940B (zh) * 2025-03-19 2025-06-20 中国人民解放军军事科学院军事医学研究院 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
US20130189279A1 (en) 2010-04-07 2013-07-25 Agency For Science, Technology And Research Binding Molecules Against Chikungunya Virus and Uses Thereof
JP2014524748A (ja) 2011-07-19 2014-09-25 グラクソ グループ リミテッド ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質
US20160145323A1 (en) 2013-07-19 2016-05-26 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU7071598A (en) 1997-04-10 1998-10-30 Erasmus University Rotterdam Diagnosis method and reagents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2005318171B2 (en) * 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
CA2545597A1 (en) 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
CN102015769B (zh) * 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
WO2009124312A2 (en) 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
HK1213481A1 (zh) 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
MA41517A (fr) 2015-04-14 2017-12-19 Univ Vanderbilt Neutralisation du virus du chikungunya à médiation par des anticorps
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519860A (ja) 2004-11-12 2008-06-12 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
US20130189279A1 (en) 2010-04-07 2013-07-25 Agency For Science, Technology And Research Binding Molecules Against Chikungunya Virus and Uses Thereof
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
JP2014524748A (ja) 2011-07-19 2014-09-25 グラクソ グループ リミテッド ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質
US20160145323A1 (en) 2013-07-19 2016-05-26 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cell Host & Microbe，2015年，Vol.18，pp.86-95，Supplemental Information Table S1
Clinical Immunology，2013年，Vol.149，pp.487-497
THE JOURNAL OF IMMUNOLOGY，2011年01月28日，Vol.186, No.5，pp.3258-3264，https://www.jimmunol.org/content/jimmunol/186/5/3258.full.pdf

Also Published As

Publication number Publication date
US12227560B2 (en) 2025-02-18
CA3040842A1 (en) 2018-04-26
AR109857A1 (es) 2019-01-30
TWI778985B (zh) 2022-10-01
WO2018073387A1 (en) 2018-04-26
IL266082A (en) 2019-06-30
CN110088131B (zh) 2022-12-06
MA46562A (fr) 2019-08-28
JP7181193B2 (ja) 2022-11-30
JP2023015301A (ja) 2023-01-31
EP3529271A1 (en) 2019-08-28
UY37449A (es) 2018-05-31
JP2025038079A (ja) 2025-03-18
IL310834A (en) 2024-04-01
IL266082B1 (en) 2024-03-01
JP2019534001A (ja) 2019-11-28
US11286295B2 (en) 2022-03-29
IL266082B2 (en) 2024-07-01
US20180127487A1 (en) 2018-05-10
JP7664212B2 (ja) 2025-04-17
CN110088131A (zh) 2019-08-02
EA201990988A1 (ru) 2019-09-30
CN115873106A (zh) 2023-03-31
TW201827461A (zh) 2018-08-01
TW202300515A (zh) 2023-01-01
US20220275063A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JP7664212B2 (ja) 抗ｃｈｉｋｖ抗体およびその使用
US11655285B2 (en) Human immunodeficiency virus neutralizing antibodies
US11192941B2 (en) Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US11597759B2 (en) Multispecific antibodies that target HIV GP120 and CD3
JP6904616B2 (ja) 緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途
US20240425568A1 (en) Combination therapies for hiv infections and uses thereof
EA042611B1 (ru) Антитела против chikv и пути их применения
HK40072519A (en) Human immunodeficiency virus neutralizing antibodies
HK40079368A (en) Human immunodeficiency virus neutralizing antibodies
HK40069391A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
HK40079368B (zh) 人免疫缺陷病毒中和抗体
HK1261190A1 (en) Human immunodeficiency virus neutralizing antibodies
HK1261190B (en) Human immunodeficiency virus neutralizing antibodies
EA041777B1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221117

R150 Certificate of patent or registration of utility model

Ref document number: 7181193

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250